Akademik Veri Yönetim Sistemi
Clinical laboratory, cilt.68, sa.10, 2022 (SCI-Expanded)
Background: COVID-19, caused by the SARS-CoV-2 virus, has infected nearly 270 million people over the past two years. We aimed to determine the exhaled CO levels of patients hospitalized with COVID-19 pneumonia and its correlation with parenchymal involvement.Methods: Between September 2021 and December 2021, 74 patients who were hospitalized in the infectious dis-eases service of our hospital and whose delta variant COVID-19 infection was confirmed with real-time PCR method were included in the study. The patients were analyzed in 3 groups: moderate COVID-19 (group 1), se-vere COVID-19 without macrophage activation syndrome (MAS) (group 2), and severe COVID-19 with MAS (group 3).Results: While it was observed that the exhaled CO levels were higher in patients in Group 3 at the time of hospi-talization than in patients in Group 1 and 2, it was determined that no significant difference was observed between the groups at the time of discharge (p < 0.001, 0.213). CT scores obtained at the time of hospitalization were also observed to be statistically significantly higher in patients in Group 3 when compared to patients in Group 1 and 2 (p = 0.002). In the correlation analysis of the exhaled CO levels and the CT scores at the time of hospitalization, a statistically significant positive correlation was observed (r = 0.628, p < 0.001). Conclusions: In COVID-19, which has a high affinity for lung tissue compared to other known viral lower respira-tory tract infections, the exhaled CO level may be a non-invasive parameter that can be used in the evaluation of parenchymal involvement and clinical course.